Mizuho raised the firm’s price target on Immuneering (IMRX) to $12 from $10 and keeps an Outperform rating on the shares.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- Two new option listings and three option delistings on October 2nd
- Immuneering’s Promising Phase 2a Data and Safety Profile Drive Buy Rating
- Immuneering Announces Public Offering to Raise $164.1M
- Immuneering price target raised to $30 from $21 at Oppenheimer
- Immuneering 18.96M share Spot Secondary priced at $9.23